Biomarker programs can generate an extraordinary range of multi-omics, imaging and clinical data. Yet volume alone does not make the next decision clearer. The harder task is determining which signals are robust, biologically relevant and ready to withstand validation. In practice, five recurring barriers often slow the path from discovery to clinical translation.¹

Insight

The main challenge isn't just processing larger amounts of data. It is preserving scientific context throughout the workflow so teams can determine whether a signal is reproducible, biologically significant and supported by the overall evidence.

The Biomarker Bottleneck Has Shifted

Analytical sensitivity and throughput once dominated conversations about biomarker study design. They still matter, but information-rich datasets have moved another problem to the foreground: teams must connect evidence across instruments, modalities and disciplines well enough to decide which candidates deserve further investment and validation.1

These barriers rarely occur in isolation. A weakness early in the workflow, such as inconsistent metadata or unclear quality criteria, can resurface later as a traceability, integration or reproducibility problem.

Bottleneck #1 – Data Readiness: Inconsistent Data Delays Analysis

Before a dataset can support a biomarker decision, researchers need confidence that samples, metadata and measurements refer to the same biological and experimental context. That means reconciling identifiers, quality criteria and file structures across multi-omics, imaging and clinical sources, a task that can consume a meaningful share of the analytical effort.

Much of this work is necessary, but not scientifically differentiating. Researchers may spend time:

• Organizing and standardizing datasets
• Resolving missing or conflicting information
• Harmonizing data across platforms and modalities

This creates a widening gap between data generation and analysis readiness. When complex datasets cannot be standardized, shared or analyzed together without extensive intervention, discovery slows, and promising evidence may never reach clinical evaluation.2

Preparing data for analysis is only the first step. Teams must also be able to move that data reliably between the platforms used to generate, process and interpret it.

Bottleneck #2 – Interoperability: Disconnected Platforms Slow Interpretation

Biomarker studies depend on technologies that were not always designed to work together. Proprietary software, incompatible formats and different analysis conventions can turn a straightforward scientific question into a series of manual exports, conversions and checks. Each workaround adds time and introduces another opportunity for inconsistency.^2-4

And moving a file successfully is not the same as transferring usable evidence. The sample history, instrument settings and analytical assumptions behind that file must travel with it.

Bottleneck #3 – Continuity: Broken Handoffs Strip Data of Context

Biomarker development depends on a chain of handoffs. At each stage, teams need access not only to the result, but also to the conditions under which it was produced and the reasoning used to interpret it. When that context is separated from the data, downstream reviewers are left to reconstruct the experiment and sometimes the decision from incomplete records.

This loss can be subtle: a renamed sample, an unrecorded preprocessing step or a quality threshold stored in a separate system. Individually, these gaps may appear manageable. Over the course of a multi-stage program, they can erode traceability and make data harder to interpret or reuse.²

Preserving data, context and analysis history across handoffs strengthens traceability and confidence in biomarker decisions.

Once data and its context remain connected across handoffs, the next challenge is evaluating evidence across modalities rather than in separate silos.

Bottleneck #4 – Integration: Siloed Modalities Limit Biological Insight

A biomarker rarely tells its full story in one modality. Molecular measurements may identify a candidate pathway, imaging may show where a signal appears in tissue and clinical data may reveal whether it tracks with disease or response. Viewed together, these layers can expose relationships that remain hidden in any single dataset.^3,4

The difficulty is that these evidence streams often reside in different systems and adhere to different quality and analysis conventions. Integration, therefore, requires more than placing datasets side by side; teams must align samples, account for technical variation and preserve enough provenance to explain how a combined result was reached.^3,4

When that alignment is missing, apparent agreement may be misleading and genuine biological relationships may be overlooked. A unified view helps teams test whether multiple lines of evidence support the same biomarker hypothesis, but the conclusion still needs to hold across studies, operators and sites.

Bottleneck #5 – Standardization: Scaling Without Consistency Undermines Reproducibility

A workflow that performs well in one laboratory does not automatically scale. As programs expand, small differences in sample handling, instrument performance, data processing and acceptance criteria can accumulate. The result may be a biomarker signal that looks convincing in one setting but is difficult to reproduce elsewhere.⁵

Standardization should make critical steps comparable without forcing every study into an identical design. Shared methods, quality controls, reference materials and traceable analysis practices give teams a common basis for judging variation and reproducing results across studies, platforms and sites.⁵

What Biomarker Programs Need to Move Forward

Because these barriers interact, solving them one at a time can move the bottleneck downstream. Biomarker programs need a connected system that supports five complementary capabilities:

• Data readiness that prepares complex datasets for analysis
• Interoperability that supports exchange across platforms
• Continuity that preserves context through each handoff
• Integration that brings multi-omics and clinical evidence together
• Standardization that enables consistent, reproducible work

Together, these capabilities help teams build a traceable body of evidence, not just a collection of datasets, so that promising signals can be challenged, reproduced and advanced with greater confidence.

Download the Biomarker Workflows ebook to explore practical ways connected technologies, automation and data infrastructure can help carry biomarker evidence from discovery through validation.

References

1. Vitorino R. Transforming clinical research: the power of high-throughput omics integration. Proteomes 2024;12:25. doi:10.3390/proteomes12030025.

2. Stark Z, Glazer D, Hofmann O, et al. A call to action to scale up research and clinical genomic data sharing. Nat Rev Genet 2025;26:141-7. doi:10.1038/s41576-024-00776-0.

3. Slobodyanyuk M, Bahcheli AT, Klein ZP, et al. Directional integration and pathway enrichment analysis for multi-omics data. Nat Commun 2024;15:5690. doi:10.1038/s41467-024-49986-4.

4. Zheng Y, Liu Y, Yang J, et al. Multi-omics data integration using ratio-based quantitative profiling with Quartet reference materials. Nat Biotechnol 2024;42:1133-49. doi:10.1038/s41587-023-01934-1.

5. Cai X, Geyer PE, Perez-Riverol Y, et al. A standardized framework for circulating blood proteomics. Nat Genet. Published online September 23, 2025. doi:10.1038/s41588-025-02319-7.